News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Moberg Derma Initiates New Study of MOB-015



11/8/2012 9:52:42 AM

Moberg Derma AB (OMX: MOB) today announces that it has received the final results from a phase II study of MOB-015 in patients with onychomycosis. The clinical efficacy was unsatisfactory, and the company has therefore decided to initiate a new study with an improved formulation.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES